Multimechanism biological profiling of tetrahydro-β-carboline analogues as selective HDAC6 inhibitors for the treatment of Alzheimer's disease

被引:2
|
作者
Liang, Ting [1 ]
Liu, Shiru [1 ]
Dang, Baiyun [1 ]
Luan, Xiaofa [1 ]
Guo, Yifan [1 ]
Steimbach, Raphael R. [2 ,3 ]
Hu, Jiadong [4 ]
Lu, Long [4 ]
Yue, Peiyu [4 ]
Wang, Ruotian [4 ]
Zheng, Meng [1 ]
Gao, Jinming [1 ]
Yin, Xia [1 ]
Chen, Xin [1 ]
机构
[1] Northwest A&F Univ, Coll Chem & Pharm, Shaanxi Key Labotory Nat Prod & Chem Biol, Yangling 712100, Peoples R China
[2] German Canc Res Ctr, Canc Drug Dev Grp, D-69120 Heidelberg, Germany
[3] Heidelberg Univ, Biosci Fac, D-69120 Heidelberg, Germany
[4] Yangling Vocat & Tech Coll, Sch Med & Chem Engn, Yangling 712100, Peoples R China
基金
中国国家自然科学基金;
关键词
HDAC6; inhibitor; Tetrahydrocarboline; Selectivity; Multimechanism; Alzheimer's disease; HISTONE DEACETYLASE INHIBITORS; ACETYLATION; ACTIVATION; DESIGN;
D O I
10.1016/j.ejmech.2024.116624
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
With the intensive research on the pathogenesis of Alzheimer's disease (AD), inhibition of HDAC6 appears to be a potential therapeutic approach for AD. In this paper, a series of tetrahydro-ss-carboline derivatives with hydroxamic acid group were fast synthesized. Among all, the most potent 15 selectively inhibited HDAC6 with IC50 of 15.2 nM and markedly increased acetylated alpha-tubulin levels. In cellular assay, 15 showed excellent neurotrophic effect by increasing the expression of GAP43 and Beta-3 tubulin markers. Besides, 15 showed neuroprotective effects in PC12 or SH-SY5Y cells against H2O2 and 6-OHDA injury through activation of Nrf2, catalase and Prx II, and significantly reduced H2O2-induced reactive oxygen species (ROS) production. In vivo, 15 significantly attenuated zebrafish anxiety-like behaviour and memory deficits in a SCOP-induced zebrafish model of AD. To sum up, multifunctional 15 might be a good lead to develop novel tetrahydrocarboline-based agents for the treatment of AD.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Discovery of novel α-carboline derivatives as glycogen synthase kinase-3β inhibitors for the treatment of Alzheimer's disease
    Chen, Huanhua
    Yu, Chong
    Liu, Wenjie
    Zhu, Chengze
    Jiang, Xiaowen
    Xu, Chang
    Liu, Wenwu
    Huang, Yaoguang
    Xu, Zihua
    Zhao, Qingchun
    ARCHIV DER PHARMAZIE, 2022, 355 (10)
  • [42] Discovery of Potent Selective HDAC6 Inhibitors with 5-Phenyl-1H-indole Fragment: Virtual Screening, Rational Design, and Biological Evaluation
    Li, Xuedong
    Wang, Chengzhao
    Chai, Xu
    Liu, Xingang
    Qiao, Kening
    Fu, Yan
    Jin, Yanzhao
    Jia, Qingzhong
    Zhu, Feng
    Zhang, Yang
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2024, 64 (15) : 6147 - 6161
  • [43] Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer's disease
    Chen, Shang-Ying
    Chen, Yuan
    Li, Yan-Ping
    Chen, Shu-Han
    Tan, Jia-Heng
    Ou, Tian-Miao
    Gu, Lian-Quan
    Huang, Zhi-Shu
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (18) : 5596 - 5604
  • [44] A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice
    Onishi, Tomohiro
    Maeda, Ryouta
    Terada, Michiko
    Sato, Sho
    Fujii, Takahiro
    Ito, Masahiro
    Hashikami, Kentaro
    Kawamoto, Tomohiro
    Tanaka, Maiko
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [45] A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer’s disease and tauopathy in mice
    Tomohiro Onishi
    Ryouta Maeda
    Michiko Terada
    Sho Sato
    Takahiro Fujii
    Masahiro Ito
    Kentaro Hashikami
    Tomohiro Kawamoto
    Maiko Tanaka
    Scientific Reports, 11
  • [46] Integrated in-silico and in-vitro assessments of HDAC6 inhibitor efficacy in mitigating amyloid beta pathology in Alzheimer's disease
    Choudhary, Gajendra
    Prajapat, Manisha
    Kaur, Gurjeet
    Singh, Harvinder
    Mahendiratta, Saniya
    Prakash, Ajay
    Medhi, Bikash
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (18): : 9720 - 9730
  • [47] Dual inhibitors of Interleukin-6 and acetylcholinesterase for treatment of Alzheimer's disease: Design, docking, synthesis and biological evaluation
    Kaur, Sukhvir
    Bansal, Yogita
    JOURNAL OF THE INDIAN CHEMICAL SOCIETY, 2021, 98 (10)
  • [48] Quinazolin-4-one Derivatives as Selective Histone Deacetylase-6 Inhibitors for the Treatment of Alzheimer's Disease
    Yu, Chao-Wu
    Chang, Pei-Teh
    Hsin, Ling-Wei
    Chern, Ji-Wang
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (17) : 6775 - 6791
  • [49] Potent and selective HDAC6 inhibitory activity of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes as novel sulfur analogues of Tubastatin A
    De Vreese, Rob
    Verhaeghe, Tom
    Desmet, Tom
    D'hooghe, Matthias
    CHEMICAL COMMUNICATIONS, 2013, 49 (36) : 3775 - 3777
  • [50] 6-Methyluracil Derivatives as Bifunctional Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease
    Semenov, Vyacheslav E.
    Zueva, Irina V.
    Mukhamedyarov, Marat A.
    Lushchekina, Sofya V.
    Kharlamova, Alexandra D.
    Petukhova, Elena O.
    Mikhailov, Anatoly S.
    Podyachev, Sergey N.
    Saifina, Lilya F.
    Petrov, Konstantin A.
    Minnekhanova, Oksana A.
    Zobov, Vladimir V.
    Nikolsky, Evgeny E.
    Masson, Patrick
    Reznik, Vladimir S.
    CHEMMEDCHEM, 2015, 10 (11) : 1863 - 1874